Kyverna Therapeutics, Inc. (KYTX) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Kyverna Therapeutics, Inc. (KYTX) Earnings Overview
As of June 23, 2026, Kyverna Therapeutics, Inc. (KYTX) reported trailing twelve-month net income of -$156M, reflecting -9.3% year-over-year growth. The company earned $-2.59 per diluted share over the past four quarters.
Looking at the long-term picture, KYTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$26M in fiscal 2021.
Kyverna Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CABA (-$175M net income), AUTL (-$289M net income, -381.4% margin), IMVT (-$506M net income), KYTX has comparable earnings metrics. Compare KYTX vs CABA →
KYTX Earnings vs Peers
Earnings metrics vs comparable public companies
KYTX Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$161M | -26.5% | -$170M | $-3.64 | - | - |
| 2024 | -$127M | -111.2% | -$143M | $-3.33 | - | - |
| 2023 | -$60M | -108.9% | -$62M | $-0.00 | - | - |
| 2022 | -$29M | -9.7% | -$29M | $-1.12 | -411.3% | -418.3% |
| 2021 | -$26M | - | -$26M | $-1.02 | -465.9% | -465.8% |
Download Data
Export KYTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
What is KYTX earnings per share (EPS)?
KYTX trailing twelve-month (TTM) diluted EPS is $-2.59, reflecting -9.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Kyverna Therapeutics, Inc.'s net income?
Kyverna Therapeutics, Inc. (KYTX) trailing twelve-month net income is $-156M as of 2025. Earnings declined -9.3% year-over-year.
Is KYTX profitable?
KYTX is not currently profitable on a TTM basis, reporting a net loss of $-156M. Net margin is N/A. Investors should monitor for a return to profitability.
What is KYTX's earnings growth rate?
KYTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are KYTX's profit margins?
Kyverna Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -64.7%.
Is KYTX growing earnings?
KYTX earnings are declining — EPS fell -9.3% year-over-year. TTM net income dropped to $-156M. This contrasts with the 5-year CAGR of N/A.
What was KYTX's best earnings year?
Kyverna Therapeutics, Inc.'s highest annual net income on record is $-26M, achieved in fiscal year 2021. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were KYTX's earnings last quarter?
KYTX's most recent reported quarter was Q1 2026. Net income was $-40M with diluted EPS of $-0.66. For a full breakdown of all quarters, see the quarterly earnings table on this page.